S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Sell every Stock except ONE (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
India launches 5G services, Modi calls it step in new era
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Hong Kong leader promises revival on China's National Day
UK train strikes and energy hikes add to a week of turmoil
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Sell every Stock except ONE (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
India launches 5G services, Modi calls it step in new era
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Hong Kong leader promises revival on China's National Day
UK train strikes and energy hikes add to a week of turmoil
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Sell every Stock except ONE (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
India launches 5G services, Modi calls it step in new era
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Hong Kong leader promises revival on China's National Day
UK train strikes and energy hikes add to a week of turmoil
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Sell every Stock except ONE (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
India launches 5G services, Modi calls it step in new era
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Hong Kong leader promises revival on China's National Day
UK train strikes and energy hikes add to a week of turmoil
NASDAQ:ARDS

Aridis Pharmaceuticals - ARDS Stock Forecast, Price & News

$0.93
+0.03 (+3.33%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.89
$0.95
50-Day Range
$0.73
$2.47
52-Week Range
$0.68
$4.34
Volume
125,605 shs
Average Volume
285,264 shs
Market Capitalization
$16.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Aridis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
975.3% Upside
$10.00 Price Target
Short Interest
Healthy
0.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.20mentions of Aridis Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.23) to ($0.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

836th out of 1,093 stocks

Pharmaceutical Preparations Industry

407th out of 547 stocks

ARDS stock logo

About Aridis Pharmaceuticals (NASDAQ:ARDS) Stock

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Receive ARDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARDS Stock News Headlines

Wave Therapeutics (WVE) Up on Update From Huntington's Study
ARDS Aridis Pharmaceuticals, Inc.
bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD
Aridis Pharmaceuticals, Inc. (ARDS)
Why Aridis Pharma Is Rising In Pre-market?
See More Headlines
Receive ARDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARDS Company Calendar

Last Earnings
8/16/2022
Today
10/01/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARDS
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+975.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-42,190,000.00
Net Margins
-1,954.56%
Pretax Margin
-1,776.79%

Debt

Sales & Book Value

Annual Sales
$1.53 million
Book Value
($0.93) per share

Miscellaneous

Free Float
15,418,000
Market Cap
$16.46 million
Optionable
Not Optionable
Beta
1.25

Key Executives

  • Dr. Vu L. Truong Ph.D. (Age 58)
    Founder, CEO, Chief Scientific Officer & Director
    Comp: $576.25k
  • Mr. Fred Kurland J.D. (Age 71)
    M.B.A., Chief Financial Officer
    Comp: $305.89k
  • Dr. Hasan Jafri M.D.
    Chief Medical Officer
  • Mr. Jeffrey J. Fessler Esq. (Age 59)
    J.D., Acting Gen. Counsel













ARDS Stock - Frequently Asked Questions

Should I buy or sell Aridis Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARDS shares.
View ARDS analyst ratings
or view top-rated stocks.

What is Aridis Pharmaceuticals' stock price forecast for 2022?

2 brokerages have issued 12 month target prices for Aridis Pharmaceuticals' stock. Their ARDS share price forecasts range from $10.00 to $10.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 975.3% from the stock's current price.
View analysts price targets for ARDS
or view top-rated stocks among Wall Street analysts.

How have ARDS shares performed in 2022?

Aridis Pharmaceuticals' stock was trading at $2.33 on January 1st, 2022. Since then, ARDS shares have decreased by 60.1% and is now trading at $0.93.
View the best growth stocks for 2022 here
.

When is Aridis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our ARDS earnings forecast
.

How were Aridis Pharmaceuticals' earnings last quarter?

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) issued its quarterly earnings data on Tuesday, August, 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.39.

What other stocks do shareholders of Aridis Pharmaceuticals own?
When did Aridis Pharmaceuticals IPO?

(ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

What is Aridis Pharmaceuticals' stock symbol?

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

How do I buy shares of Aridis Pharmaceuticals?

Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aridis Pharmaceuticals' stock price today?

One share of ARDS stock can currently be purchased for approximately $0.93.

How much money does Aridis Pharmaceuticals make?

Aridis Pharmaceuticals (NASDAQ:ARDS) has a market capitalization of $16.46 million and generates $1.53 million in revenue each year. The company earns $-42,190,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis.

How can I contact Aridis Pharmaceuticals?

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct, San Jose CA, 95138. The official website for the company is www.aridispharma.com. The company can be reached via phone at (408) 385-1742, via email at jwong@bplifescience.com, or via fax at 408-960-3822.

This page (NASDAQ:ARDS) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.